Interestingly, higher proportions of tumor‐infiltrating CD40+ or CD86+ pDCs were linked to longer PFS, whereas higher proportions of tumor‐infiltrating CD80+ cDC2s or pDCs foresaw worse clinical outcome as it was linked with shorter PFS (Figure 2b, Supplementary figure 3e). This evidence concerns the gene CD86 and neoplasm.